{"schema_version":"secwatch.filing_event.v1","accession":"0001425450-22-000101","form_type":"8-K","ticker":"KIDS","cik":"0001425450","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.613557+00:00","generated_at":"2026-06-22T21:31:46.417967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OrthoPediatrics Q3 revenue up 39% to $35M; cuts FY2022 revenue guidance to $124-125M","bullets":["Revenue $35.0M (+39% YoY); organic growth ~22% excluding MD Ortho and Pega Medical contributions of $4.4M.","Net income $18.5M ($0.87 diluted EPS) vs net loss ($2.2M) in Q3 2021, includes $23M fair value adjustment.","FY2022 revenue guidance lowered to $124-125M (from $127-130M); organic guidance $113-114M (15-16% growth).","Adjusted EBITDA $1.9M vs $0.5M in Q3 2021; cash and equivalents $121.6M with no debt drawn.","Company cites RSV infections and staffing shortages as September headwinds; Pega Medical acquisition closed in July."],"urls":{"canonical":"https://secwatch.observer/filing/0001425450-22-000101","json":"https://secwatch.observer/filing/0001425450-22-000101.json","markdown":"https://secwatch.observer/filing/0001425450-22-000101.md","text":"https://secwatch.observer/filing/0001425450-22-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425450/000142545022000101/0001425450-22-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425450/000142545022000101/kids-20221031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:31:46.417967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f407e27c35cd0cd869bb2ee2905151533aa486db","claim":"ORTHOPEDIATRICS CORP reported third quarter ended September 30, 2022 results: revenue $35.0 million, net income $18.5 million, EPS $0.87 per diluted share.","evidence_excerpt":"Total revenue for the third quarter of 2022 was $35.0 million, a 39% increase compared to $25.1 million for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425450/000142545022000101/0001425450-22-000101-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$35.0 million"},{"label":"Net income","value":"$18.5 million"},{"label":"EPS","value":"$0.87 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fe081d9dbdd3df27ca8dd22127efa84b7d18694a","claim":"ORTHOPEDIATRICS CORP reported full year 2022 results: revenue $124 million to $125 million. Guidance lowered.","evidence_excerpt":"For full year 2022, the Company now expects its full year revenue to be in the range of $124 million to $125 million, updated from its previous guidance range of $127 million to $130 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425450/000142545022000101/0001425450-22-000101-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$124 million to $125 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}